Review Article

Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis

Table 2

Patient population and clinical scenario among included studies.

Patient populationStudyInvestigational drug

STEMIAPEX-MI [28]Pexelizumab
COMMA [16]
COMPLY [16]
VCU-ART3 [34]Anakinra
NSTEMIMRC-ILA Heart Study [35]Anakinra
MI (STEMI and NSTEMI)CANTOS [17]Canakinumab
LATITUDE TIMI 60 [43]Losmapimod
COLCOT [37]Colchicine
ACS (STEMI, NSTEMI, or UA)SOLID TIMI 52 [38]Darapladib
FRANCIS [41]Varespladib
VISTA-16 [40]Varespladib
CABGPRIMO CABG 1 [32]Pexelizumab
PRIMO CABG 2 [31]
Pexelizumab Study Investigators [30]
SELECT-CABG [42]Inclacumab
Stable CADSTABILITY [39]Darapladib
LoDoCo [36]Colchicine

Study with subgroup analysis of its primary end points.